CClinicalTrials.gg
CompletedNCT02751021SAPAADUpdated Apr 2, 2026

Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction

An interventional study of pacemaker diagnostic algorithm and Attended cardiorespiratory sleep study in Sleep Apnea, Arrhythmias, Cardiac and Cardiac Diastolic Function, sponsored by University Hospital, Caen. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by University Hospital, Caen · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Little is known about potential relationships between sleep apnea, plasma aldosterone and diastolic dysfunction which is a very frequent finding among patients requiring permanent cardiac pacing. Sleep apnea is often under diagnosed by clinical examination. Confirmation tests are expensive and access is limited. A specific algorithm available in a recent pacemaker allows assessing breathing variations using minute ventilation sensor, with a good agreement between the respiratory disturbance index and polysomnography results for the diagnosis of severe sleep apnea.

The purpose of the study is to examine the diagnostic accuracy of a new pacemaker algorithm for the diagnosis of obstructive sleep apnea in patients presenting with diastolic dysfunction. The investigators also aim to highlight a correlation between plasma aldosterone levels and the severity of sleep apnea, with a reversal effect of ventilation therapy in this specific population.

02

Conditions studied

  • Sleep Apnea
  • Arrhythmias, Cardiac
  • Cardiac Diastolic Function
  • Hyperaldosteronism
03

In context

Sleep Apnea Syndromes

2,162 studies on the registry are indexed under Sleep Apnea Syndromes; 290 are open to participants now.

This study's enrollment of 66 is above the median of 53 across 1,386 interventional studies indexed under Sleep Apnea Syndromes.

Browse Sleep Apnea Syndromes studies →

Lead sponsor

University Hospital, Caen is the lead sponsor of 505 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • indication for permanent cardiac pacing (third degree atrioventricular block, second degree atrioventricular block mobitz 2 type, symptomatic sinus node dysfunction including brady-tachy form of sick sinus syndrome or bradyarrhythmia)
  • Diastolic dysfunction diagnosed at the transthoracic echocardiography

Exclusion criteria

Exclusion Criteria:

  • younger than 18 years old
  • lack of informed consent form
  • impossibility to fit in the scheduled study plan
  • indication for cardiac resynchronization or left ventricular ejection fraction lower than 45%
  • indication for epicardial pacemaker, known severe sleep apnea treated by continuous positive airway pressure
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Other
    Sleep apnea diagnosis

    The intervention is the use of the pacemaker diagnostic algorithm named Sleep Apnea Monitoring to detect sleep apnea and the attended cardiorespiratory sleep study to confirm the diagnostic.

    Other: pacemaker diagnostic algorithm · Other: Attended cardiorespiratory sleep study

Interventions

  • Otherpacemaker diagnostic algorithm

    evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea

  • OtherAttended cardiorespiratory sleep study

    sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis

06

What researchers measure

Primary outcomes

  1. Comparison between respiratory disturbance index recorded the sleep study night and Apnea hypopnea index

    number of apneas and hypopneas per hour (5 hours recorded by night) evaluated by the pacemaker algorithm during the night of the attended cardiorespiratory sleep study compared to the apnea hypopnea index evaluated by the portable monitor during the attended cardiorespiratory sleep study

    Time frame: 2 months after pacemaker implantation

  2. Comparison between the mean respiratory disturbance index of the last month and Apnea hypopnea index

    Average value of respiratory disturbance index recorded each night during the last month compared to the apnea hypopnea index evaluated by the portable monitor during the attended cardiorespiratory sleep study

    Time frame: 2 months after pacemaker implantation

Secondary outcomes

  1. Measurement of plasmatic aldosterone and correlation with apnea hypopnea index

    Time frame: 2 months after pacemaker implantation and one month after the beginning of continuous positive airway pressure (CPAP) therapy in apneic patients

07

Study locations

1 site
  • Caen University Hospital
    Caen, Normandy 14000, France
08

References and documents

Publications

  • Champ-Rigot L, Ferchaud V, Prevost JN, Moirot P, Pellissier A, Legallois D, Alexandre J, Scanu P, Morello R, Saloux E, Milliez PU. Rationale and Design for a Monocentric Prospective Study: Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction (SAPAAD Study). Clin Med Insights Cardiol. 2018 Jan 8;12:1179546817751628. doi: 10.1177/1179546817751628. eCollection 2018. PubMed 29343998 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02751021
Lead sponsor
University Hospital, Caen
Collaborators
LivaNova
Responsible party
Sponsor
First posted
Apr 26, 2016
Start date
Jun 22, 2016
Primary completion
Jun 2019
Completion
Jun 2019
Last update
Apr 2, 2026

Study contacts

Laure CHAMP-RIGOT, MD
principal investigator · University Hospital, Caen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion